The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Activity of the FcRH5 bispecific antibody cevostamab after prior BCMA therapy in multiple myeloma
Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the activity of the FcRH5-targeting bispecific antibody cevostamab in patients with multiple myeloma previously treated with BCMA-directed therapies. He notes that responses appear more frequent after prior CAR T-cell therapy than after BCMA-directed bispecific antibodies, potentially reflecting differences in treatment sequencing, immune recovery, and T-cell exhaustion, though these observations remain exploratory. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
